Publicaciones (67) Publicaciones en las que ha participado algún/a investigador/a

2016

  1. A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia

    British Journal of Cancer, Vol. 114, Núm. 11, pp. 1191-1198

  2. A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer

    Gynecologic Oncology, Vol. 142, Núm. 1, pp. 62-69

  3. Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and crosspriming

    Cancer Research, Vol. 76, Núm. 20, pp. 5994-6005

  4. Adjuvant radiation therapy in resected high-grade localized skeletal osteosarcomas treated with neoadjuvant chemotherapy: Long-term outcomes

    Radiotherapy and Oncology, Vol. 119, Núm. 1, pp. 30-34

  5. Anti-PD1-induced pneumonitis: Capturing the hidden enemy

    Clinical Cancer Research, Vol. 22, Núm. 24, pp. 5956-5958

  6. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial

    The Lancet, Vol. 387, Núm. 10031, pp. 1909-1920

  7. Bringing model-based prediction to oncology clinical practice: A review of Pharmacometrics principles and applications

    Oncologist, Vol. 21, Núm. 2, pp. 220-232

  8. Cancer immunotherapy with immunomodulatory anti-CD137 and anti–PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells

    Cancer Discovery, Vol. 6, Núm. 1, pp. 71-79

  9. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): A randomised, double-blind, placebo-controlled phase 3 trial

    The Lancet, Vol. 387, Núm. 10023, pp. 1066-1074

  10. Circulating melanoma exosomes as diagnostic and prognosis biomarkers

    Clinica Chimica Acta, Vol. 454, pp. 28-32

  11. Clinical significance of cellular and acellular mucin pools in rectal carcinoma following preoperative chemoradiotherapy

    Clinical and Translational Oncology, Vol. 18, Núm. 7, pp. 714-721

  12. Clinical use of ipilimumab for metastatic melanoma in Spain: towards a more consistent approach

    Clinical and Translational Oncology, Vol. 18, Núm. 10, pp. 1044-1050

  13. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients

    European Journal of Cancer, Vol. 69, pp. 127-134

  14. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy

    European Journal of Immunology, Vol. 46, Núm. 3, pp. 513-522

  15. Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies

    Annals of Oncology, Vol. 27, Núm. 7, pp. 1190-1198

  16. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes

    Brachytherapy, Vol. 15, Núm. 2, pp. 127-135

  17. Double-blind, placebo-controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-Expressing platinum-resistant ovarian Cancer (PENELOPE)

    Journal of Clinical Oncology, Vol. 34, Núm. 21, pp. 2516-2525

  18. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up

    Annals of Oncology, Vol. 27, Núm. 1, pp. 16-41

  19. Emerging opportunities and challenges in cancer immunotherapy

    Clinical Cancer Research, Vol. 22, Núm. 8, pp. 1845-1855

  20. Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer

    Expert Opinion on Emerging Drugs, Vol. 21, Núm. 3, pp. 267-282